Mitochondrial transcription factor A (mtTFA), also known by its alternative designation, TFAM (transcription factor A, mitochondrial), is a pivotal nuclear-encoded protein that migrates to the mitochondria. Within these essential cellular organelles, mtTFA embarks on its role of initiating mitochondrial DNA (mtDNA) transcription and replication. Beyond the mere initiation of these processes, mtTFA demonstrates specificity in binding to mtDNA, subsequently packaging this genetic material into compact nucleoid structures. This act is more than just organizational; it serves to shield the mtDNA, ensuring its stability. As mitochondria are charged with the onus of ATP production, the principal energy molecule of the cell, mtTFA's regulatory influence over mitochondrial gene expression is undeniably crucial. Its role firmly positions mtTFA as a linchpin in the smooth functioning and biogenesis of mitochondria.
mtTFA inhibitors emerge as meticulously designed agents that zero in on and modulate the activity profile of mtTFA. The intrigue surrounding these inhibitors lies in their ability to recalibrate the transcription and replication dynamics of mtDNA. Such alterations, rooted in the inhibition of mtTFA, could ripple out to impact mitochondrial gene expression. A disruption of this magnitude might subsequently reverberate through mitochondrial operations. The scientific exploration of mtTFA inhibitors provides a unique vantage point, allowing researchers a closer look into the labyrinthine regulatory structures that oversee mitochondrial biogenesis and operational protocols. As the study of these inhibitors continues, the scientific community stands poised to deepen its understanding of the nuances of mitochondrial biology, the preservation of mtDNA, and the broader ramifications of mitochondrial operational anomalies on the overall health and functionality of cells.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Doxycycline-d6 | 564-25-0 unlabeled | sc-218274 | 1 mg | $16500.00 | ||
Doxycycline has been shown to inhibit mitochondrial biogenesis, which could potentially result in decreased mtTFA expression by reducing the demand for mitochondrial transcription. | ||||||
Chloramphenicol | 56-75-7 | sc-3594 | 25 g | $90.00 | 10 | |
Chloramphenicol inhibits mitochondrial protein synthesis. A decrease in mitochondrial proteins might lead to a compensatory down-regulation of mtTFA. | ||||||
Ritonavir | 155213-67-5 | sc-208310 | 10 mg | $124.00 | 7 | |
Ritonavir, an antiretroviral drug, can impact mitochondrial function, potentially leading to decreased mtTFA expression through feedback mechanisms. | ||||||
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $87.00 | 9 | |
Valproic acid can cause mitochondrial dysfunction. This might lead to changes in mtTFA levels as a compensatory response. | ||||||
3′-Azido-3′-deoxythymidine | 30516-87-1 | sc-203319 | 10 mg | $61.00 | 2 | |
3′-Azido-3′-deoxythymidine's (Zidovudine) potential mitochondrial toxicity might affect mtTFA expression by altering mitochondrial transcription demands. | ||||||
Tenofovir | 147127-20-6 | sc-204335 sc-204335A | 10 mg 50 mg | $157.00 $646.00 | 11 | |
This antiretroviral drug's influence on mitochondrial function could potentially decrease mtTFA expression levels. | ||||||
Atovaquone | 95233-18-4 | sc-217675 | 10 mg | $270.00 | 2 | |
By inhibiting mitochondrial electron transport, atovaquone might indirectly lead to decreased mtTFA expression. | ||||||
Arsenic(III) oxide | 1327-53-3 | sc-210837 sc-210837A | 250 g 1 kg | $89.00 $228.00 | ||
Arsenic trioxide can affect mitochondrial function, potentially leading to decreased mtTFA expression as a cellular response. | ||||||
Antimycin A | 1397-94-0 | sc-202467 sc-202467A sc-202467B sc-202467C | 5 mg 10 mg 1 g 3 g | $55.00 $63.00 $1675.00 $4692.00 | 51 | |
By inhibiting mitochondrial electron transport, antimycin A might lead to a decrease in mtTFA expression. | ||||||